Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 8/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071132 | 0.84 | F2RL1 (0.64) | F2RL1HPGDTSHRKMT2AMEN1 | |
| SCHEMBL31488 | 0.83 | F2RL1 (0.60) | F2RL1HPGDTSHRKMT2AMEN1 | |
| SCHEMBL31560 | 0.83 | F2RL1 (0.63) | F2RL1HPGDKMT2AMEN1NPC1 | |
| SCHEMBL15071141 | 0.81 | F2RL1 (0.61) | F2RL1HPGDKMT2AMEN1NPC1 | |
| SCHEMBL31503 | 0.80 | ADORA2A (0.53) | PLA2G7HPGDTSHRKMT2AMEN1 | |
| SCHEMBL15071100 | 0.80 | F2RL1 (0.77) | F2RL1HPGDTSHRKMT2AMEN1 | |
| SCHEMBL15071143 | 0.78 | F2RL1 (0.74) | F2RL1HPGDTSHRKMT2AMEN1 | |
| SCHEMBL15071127 | 0.78 | F2RL1 (0.62) | F2RL1HPGDKMT2ALMNAALDH1A1 | |
| SCHEMBL15071138 | 0.78 | F2RL1 (0.62) | F2RL1HPGDTSHRNPC1ALDH1A1 | |
| SCHEMBL15071130 | 0.78 | F2RL1 (0.62) | F2RL1HPGDKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012026765-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | (주)네오팜 (KR) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, FPR2 | F2RL1 1/4885PLA2G7 152/4885HPGD 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.